Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 51 articles: HTML format

Single Articles

October 2026
1. KANEKO GO, Igarashi D, Morita M, Tsubota S, et al
   Real-world Outcomes of First-line Enfortumab Vedotin Plus Pembrolizumab in Elderly Patients With Advanced Urothelial Carcinoma.
   Anticancer Res. 2026;46:5715-5727.
   PubMed     Abstract available
   
   
   
2. FUKUSHIMA H, Yoshida S, Yajima S, Hirakawa A, et al
   Complete Response Durability After TAR-200 and Nadofaragene Firadenovec in BCG-unresponsive Bladder CIS.
   Anticancer Res. 2026;46:5729-5735.
   PubMed     Abstract available
   
   
   
3. WAKAMIYA T, Iwagami S, Enyo N, Shibano S, et al
   Structured Symptom Monitoring During Enfortumab Vedotin Plus Pembrolizumab for Advanced or Metastatic Urothelial Carcinoma: Multicenter Retrospective Study.
   Anticancer Res. 2026;46:5639-5650.
   PubMed     Abstract available
   
   
   August 2026
4. KOBARI Y, Nakajima N, Saito A, Katsurayama N, et al
   Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
   Anticancer Res. 2026;46:4453-4460.
   PubMed     Abstract available
   
   
   July 2026
5. SASAKI Y, Endo Y, Ochiai T, Kin M, et al
   Gene Deletion of Microsomal Prostaglandin E Synthase-1 Suppresses Chemical Carcinogen-induced Bladder Cancer.
   Anticancer Res. 2026;46:3651-3659.
   PubMed     Abstract available
   
   
   June 2026
6. KLATTE T, Hofbauer SL, Ebert J, Ecke TH, et al
   Real-world Patterns and Trends of Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer: Insights from a Large Prospective German Cohort.
   Anticancer Res. 2026;46:3333-3342.
   PubMed     Abstract available
   
   
   
7. SABBADINI P, Paganoni E, Galeasso L, Depetris I, et al
   Basaloid Urothelial Carcinoma Presenting With Paraneoplastic Hypercalcemia and Leukocytosis: A Case Report and Literature Review.
   Anticancer Res. 2026;46:3517-3522.
   PubMed     Abstract available
   
   
   May 2026
8. GOTO K, Ando K, Motoi N, Iizuka T, et al
   Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer.
   Anticancer Res. 2026;46:2445-2453.
   PubMed     Abstract available
   
   
   
9. FURUBAYASHI N, Tsujita J, Takayama A, Shiraishi Y, et al
   Real-world Delivery and Outcomes of Intravesical BCG for Non-muscle-invasive Bladder Cancer.
   Anticancer Res. 2026;46:2599-2608.
   PubMed     Abstract available
   
   
   
10. THI TN, Nguyen VT, Thanh HD, Kwon SY, et al
    Inhibition of AP-1 Reduces CD46-mediated Invasion of Bladder and Colon Cancer Cells.
    Anticancer Res. 2026;46:2525-2539.
    PubMed     Abstract available
    
    
    April 2026
11. GUTIU AG, Marrah AJ, Voss BB, Cowan BC, et al
    Allow Aloe to Do the Work: Aloe vera Constrains Growth of Bladder Cancer Cells and Modulates Expression of Key Costimulatory Molecules.
    Anticancer Res. 2026;46:1883-1892.
    PubMed     Abstract available
    
    
    
12. SATO T, Sano T, Adachi H, Ikeda Y, et al
    Clinicopathological Characteristics and Clinical Course of Non-muscle-invasive Bladder Cancer Secondary to Radical Nephroureterectomy.
    Anticancer Res. 2026;46:2077-2086.
    PubMed     Abstract available
    
    
    
13. SUGIYAMA Y, Naiki T, Morikawa T, Odagiri K, et al
    Prognostic Impact of Early GNRI Sustainability in Metastatic Urothelial Carcinoma Receiving Pembrolizumab.
    Anticancer Res. 2026;46:2187-2198.
    PubMed     Abstract available
    
    
    
14. LIAO CH, Chang WS, Chang SY, Wang YC, et al
    Insights From Matrix Metalloproteinase-2 Genotypes to Decipher the Genetic Architecture of Bladder Cancer Risk.
    Anticancer Res. 2026;46:1861-1874.
    PubMed     Abstract available
    
    
    December 2025
15. KOBARI Y, Iizuka J, Kondo H, Ichioka M, et al
    Renal Function With Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study in Japan.
    Anticancer Res. 2025;45:5645-5654.
    PubMed     Abstract available
    
    
    November 2025
16. DELL'ATTI L
    Management of Bladder Cancer During Pregnancy: A Narrative Review.
    Anticancer Res. 2025;45:4689-4695.
    PubMed     Abstract available
    
    
    October 2025
17. NISHIO K, Hirosuna K, Uchimoto T, Niigawa H, et al
    Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial Carcinoma.
    Anticancer Res. 2025;45:4575-4583.
    PubMed     Abstract available
    
    
    August 2025
18. ZHENG M, Lu J, Yu W, Li Y, et al
    Nucleoporin 188 as a Predictive Biomarker of Poor Prognosis in Muscle-invasive Bladder Cancer.
    Anticancer Res. 2025;45:3245-3261.
    PubMed     Abstract available
    
    
    
19. OKADA K, Naito Y, Irie S, Nakamoto C, et al
    Novel UF-5000-based Detection, Integrating Inflammatory Parameters, for Urothelial Carcinoma of the Urinary Bladder.
    Anticancer Res. 2025;45:3531-3541.
    PubMed     Abstract available
    
    
    June 2025
20. MATSUO T, Miyata Y, Harada J, Itoh I, et al
    Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer.
    Anticancer Res. 2025;45:2563-2573.
    PubMed     Abstract available
    
    
    
21. ONISHI T, Sekito S, Shibahara T, Yabana T, et al
    Randomized Study of Short-time Continuous Saline Irrigation After Transurethral Resection in Non-muscle Invasive Bladder Cancer.
    Anticancer Res. 2025;45:2653-2660.
    PubMed     Abstract available
    
    
    May 2025
22. FURUBAYASHI N, Mochida M, Kijima A, Fujimoto Y, et al
    Treatment Outcomes After Progression With Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma.
    Anticancer Res. 2025;45:2185-2193.
    PubMed     Abstract available
    
    
    
23. TUNG CH, Lin SH, Chang KP, Xu YW, et al
    Light Bladder Net: Non-invasive Bladder Cancer Prediction by Weighted Deep Learning Approaches and Graphical Data Transformation.
    Anticancer Res. 2025;45:1953-1964.
    PubMed     Abstract available
    
    
    March 2025
24. YAMAGUCHI N, Morizane S, Yamane H, Shimizu R, et al
    Perioperative and Oncologic Outcomes of Robot-assisted Versus Laparoscopic Radical Cystectomy in Patients With Bladder Cancer.
    Anticancer Res. 2025;45:1215-1224.
    PubMed     Abstract available
    
    
    December 2024
25. JARADAT JH, Idrissi YA, Saeed A
    HOOK3 Amplification in Bladder Urothelial Carcinoma: Insights from Gene Expression and Survival Analysis.
    Anticancer Res. 2024;44:5175-5185.
    PubMed     Abstract available
    
    
    October 2024
26. DIONESE M, Bimbatti D, Pierantoni F, Lai E, et al
    Systemic Inflammation Indexes and Risk of Immune-related Adverse Events in Patients With Metastatic Urothelial Carcinoma Treated With Immunotherapy.
    Anticancer Res. 2024;44:4379-4386.
    PubMed     Abstract available
    
    
    September 2024
27. SATO M, Sato T, Hozumi C, Han Q, et al
    [(11)C]Methionine PET vs. [(18)F]Fluorodeoxyglucose PET Whole-body Imaging to Determine the Extent of Methionine-addiction Compared to Glucose-addiction of Primary and Metastatic Cancer of the Trunk in Patients.
    Anticancer Res. 2024;44:3891-3898.
    PubMed     Abstract available
    
    
    August 2024
28. ZEKAN D, Hogan T, Jackson B, Jackson G, et al
    The Novel Platinum Analog Dicycloplatin Provides Reliable Growth Inhibition of Urothelial Carcinoma Cells In Vitro.
    Anticancer Res. 2024;44:3243-3254.
    PubMed     Abstract available
    
    
    May 2024
29. CHEN CH, Chen YC, Chang YC, Hung CH, et al
    Taurine Rescues Cancer-induced Atrophy in Human Skeletal Muscle Cells via Ameliorating the Inflammatory Tumor Microenvironment.
    Anticancer Res. 2024;44:1963-1971.
    PubMed     Abstract available
    
    
    
30. KOBATAKE K, Ikeda K, Kohada Y, Tasaka R, et al
    Muscle-Invasive Bladder Cancer With Hydronephrosis Exhibits a High Frequency of Mutations in Fibroblast Growth Factor Receptor 3 Gene.
    Anticancer Res. 2024;44:1947-1954.
    PubMed     Abstract available
    
    
    
31. HUBER F, Wolf I, Storz J, Schultze-Seemann S, et al
    Antibody-dye Conjugates Targeting EGFR and HER2 for the Photoimmunotherapy of Bladder Cancer.
    Anticancer Res. 2024;44:1837-1844.
    PubMed     Abstract available
    
    
    
32. FUKUOKAYA W, Akazawa K, Kimura T
    Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma.
    Anticancer Res. 2024;44:2117-2123.
    PubMed     Abstract available
    
    
    
33. FUCHIZAWA H, Ando K, Motoi N, Iizuka T, et al
    STAT3 Contributes a Favorable Response to Pembrolizumab Through IFN-gamma-induced Apoptosis in Urothelial Cancer.
    Anticancer Res. 2024;44:1925-1930.
    PubMed     Abstract available
    
    
    April 2024
34. SATO R, Watanabe K, Matsushita Y, Watanabe H, et al
    Assessment of Therapeutic Effects of Combined Treatment With Cisplatin and Anti-mouse Programmed Death (PD)-1 Antibody in a Mouse Urothelial Cancer Model.
    Anticancer Res. 2024;44:1417-1423.
    PubMed     Abstract available
    
    
    
35. FURUBAYASHI N, Minato A, Tomoda T, Hori Y, et al
    Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study.
    Anticancer Res. 2024;44:1675-1681.
    PubMed     Abstract available
    
    
    March 2024
36. YU SH, Wang CY, Wang SS, Li JR, et al
    Comparing Clinical Efficacy of Different Bacillus Calmette-Guerin Strains in Patients With T1 High Grade Bladder Cancer.
    Anticancer Res. 2024;44:1299-1307.
    PubMed     Abstract available
    
    
    
37. SHINDO T, Hashimoto K, Takahashi A, Miyamoto S, et al
    Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
    Anticancer Res. 2024;44:1271-1279.
    PubMed     Abstract available
    
    
    February 2024
38. ONER M, Lin E, Chiu KY, Chen MC, et al
    p35/CDK5 Regulates Bladder Cancer Proliferation and Migration and Promotes Higher Tumor Grade and Poor Survival Rate in Patients With Bladder Cancer.
    Anticancer Res. 2024;44:543-553.
    PubMed     Abstract available
    
    
    December 2023
39. FURUBAYASHI N, Minato A, Tomoda T, Hori Y, et al
    Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study.
    Anticancer Res. 2023;43:5689-5698.
    PubMed     Abstract available
    
    
    November 2023
40. NISHIYAMA N, Kita Y, Ito K, Kato M, et al
    Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
    Anticancer Res. 2023;43:5041-5050.
    PubMed     Abstract available
    
    
    October 2023
41. SOMMER U, Grosser M, Aust D, Joehrens K, et al
    PD-L1 mRNA Detection in Immunohistochemically Negative Patients: A Complementary Method for a Better Treatment Selection?
    Anticancer Res. 2023;43:4365-4371.
    PubMed     Abstract available
    
    
    September 2023
42. MINATO A, Kimuro R, Ohno D, Tanigawa K, et al
    Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
    Anticancer Res. 2023;43:4055-4060.
    PubMed     Abstract available
    
    
    
43. KASHIWAGI E, Shiota M, Inokuchi J, Tsukahara S, et al
    Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies.
    Anticancer Res. 2023;43:4249-4254.
    PubMed     Abstract available
    
    
    August 2023
44. TACHIBANA M, Tsubouchi K, Fukuhara Y, Aoyagi C, et al
    Factors Related to Overactive Bladder-like Symptoms in Bladder Cancer.
    Anticancer Res. 2023;43:3607-3613.
    PubMed     Abstract available
    
    
    
45. ARAI T, Sazuka T, Oka R, Tsukamoto R, et al
    Investigation on the Usefulness of Photodynamic Diagnosis-assisted Targeted Bladder Biopsy: Japanese Real-world Study.
    Anticancer Res. 2023;43:3615-3621.
    PubMed     Abstract available
    
    
    May 2023
46. SANO T, Aizawa R, Ito K, Nakamura K, et al
    Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma.
    Anticancer Res. 2023;43:2119-2126.
    PubMed     Abstract available
    
    
    April 2023
47. YAMAGUCHI N, Morizane S, Yumioka T, Shimizu R, et al
    Effect of Adjuvant Systemic Chemotherapy on Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma.
    Anticancer Res. 2023;43:1725-1730.
    PubMed     Abstract available
    
    
    
48. LUZHA J, Nass N, Czapiewski P, Schroeder N, et al
    Expression of Eukaryotic Translation Initiation Factors in the Urothelial Carcinoma of the Bladder.
    Anticancer Res. 2023;43:1437-1448.
    PubMed     Abstract available
    
    
    
49. LEE YH, Wu RC, Mai HC, Huang WL, et al
    The Regulatory Role of Nuclear Respiratory Factor 1 in Bladder Cancer Cells.
    Anticancer Res. 2023;43:1521-1531.
    PubMed     Abstract available
    
    
    March 2023
50. CHEN SY, Chao CN, Huang HY, Zhao PW, et al
    Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and Bladder Urothelial Carcinoma Cells.
    Anticancer Res. 2023;43:1175-1184.
    PubMed     Abstract available
    
    
    
51. LI JR, Wang SS, Lu K, Chen CS, et al
    First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
    Anticancer Res. 2023;43:1331-1339.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum